These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16493083)

  • 1. Visualization of p53(264-272)/HLA-A*0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptor.
    Zhu X; Belmont HJ; Price-Schiavi S; Liu B; Lee HI; Fernandez M; Wong RL; Builes J; Rhode PR; Wong HC
    J Immunol; 2006 Mar; 176(5):3223-32. PubMed ID: 16493083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.
    Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y
    J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.
    Belmont HJ; Price-Schiavi S; Liu B; Card KF; Lee HI; Han KP; Wen J; Tang S; Zhu X; Merrill J; Chavillaz PA; Wong JL; Rhode PR; Wong HC
    Clin Immunol; 2006 Oct; 121(1):29-39. PubMed ID: 16807113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers.
    Whitelegg AM; Oosten LE; Jordan S; Kester M; van Halteren AG; Madrigal JA; Goulmy E; Barber LD
    J Immunol; 2005 Aug; 175(3):1706-14. PubMed ID: 16034111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity.
    Card KF; Price-Schiavi SA; Liu B; Thomson E; Nieves E; Belmont H; Builes J; Jiao JA; Hernandez J; Weidanz J; Sherman L; Francis JL; Amirkhosravi A; Wong HC
    Cancer Immunol Immunother; 2004 Apr; 53(4):345-57. PubMed ID: 14610621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
    Held G; Neumann F; Sturm C; Kaestner L; Dauth N; de Bruijn DR; Renner C; Lipp P; Pfreundschuh M
    Int J Cancer; 2008 Oct; 123(8):1841-7. PubMed ID: 18688854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of HLA-A*0201 bound tumor associated antigens on a peptide pulsed B cell line.
    Wataya H; Kamikawaji N; Nakanishi Y; Takayama K; Hara N; Sasazuki T
    Hum Immunol; 2001 Feb; 62(2):125-32. PubMed ID: 11182221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
    Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
    J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC allele-specific molecular features determine peptide/HLA-A2 conformations that are recognized by HLA-A2-restricted T cell receptors.
    Wang Z; Turner R; Baker BM; Biddison WE
    J Immunol; 2002 Sep; 169(6):3146-54. PubMed ID: 12218132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting activity of a TCR/IL-2 fusion protein against established tumors.
    Wen J; Zhu X; Liu B; You L; Kong L; Lee HI; Han KP; Wong JL; Rhode PR; Wong HC
    Cancer Immunol Immunother; 2008 Dec; 57(12):1781-94. PubMed ID: 18369620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.
    Justesen S; Buus S; Claesson MH; Pedersen AE
    Immunology; 2007 Nov; 122(3):326-34. PubMed ID: 17610503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
    Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
    Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific roles of each TCR hemichain in generating functional chain-centric TCR.
    Nakatsugawa M; Yamashita Y; Ochi T; Tanaka S; Chamoto K; Guo T; Butler MO; Hirano N
    J Immunol; 2015 Apr; 194(7):3487-500. PubMed ID: 25710913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells.
    Epel M; Ellenhorn JD; Diamond DJ; Reiter Y
    Cancer Immunol Immunother; 2002 Nov; 51(10):565-73. PubMed ID: 12384808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC recognition by hapten-specific HLA-A2-restricted CD8+ CTL.
    Gagnon SJ; Wang Z; Turner R; Damirjian M; Biddison WE
    J Immunol; 2003 Sep; 171(5):2233-41. PubMed ID: 12928367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.